According to our new research study on "Oscillometry Market Forecast to 2031 -Global Analysis - by Product, Technology, Application, and End User," the market is anticipated to grow from US$168.30 Million in 2024 to US$242.66 Million by 2031; the market is expected to register a CAGR of 5.5% from 2025 to 2031. Oscillometry Market growth is attributed to the growing demand for non-invasive and patient-friendly diagnostic tools, growing burden of respiratory diseases such as asthma and COPD, and technological advancements and regulatory support for home monitoring.

Oscillometry is a non-invasive pulmonary function testing technique used to assess respiratory mechanics during normal breathing. It measures airway resistance and reactance by superimposing small pressure oscillations on tidal breathing, making it especially suitable for children, elderly patients, and individuals unable to perform forced spirometry. Oscillometry is valuable in detecting early airway dysfunction, particularly in asthma, chronic obstructive pulmonary disease (COPD), and other obstructive or restrictive lung disorders. Its simplicity, patient-friendly nature, and ability to provide sensitive, effort-independent measurements support its growing adoption in clinical practice and home-based respiratory monitoring.

The Oscillometry Market in North America is segmented into the US, Canada, and Mexico. The US oscillometry market is expanding in response to the persistent and significant burden of respiratory diseases, heightened clinical recognition of oscillometry's diagnostic advantages, and ongoing innovations in oscillometry devices. In 2022, an estimated 26.8 million Americans, or 8.2% of the population, had current asthma, according to the CDC's National Health Interview Survey, highlighting a substantial population requiring pulmonary function assessment. Furthermore, among those with current asthma, 42.4% experienced an asthma attack in the past year, emphasizing ongoing clinical management needs. Chronic obstructive pulmonary disease (COPD)-a major driver of respiratory diagnostics-remained prevalent in 2023, with 3.8% of US adults age 18 or older having a diagnosed COPD, according to CDC age-adjusted estimates. These high prevalences of asthma and COPD drive demand for effective lung function testing, particularly in patients who struggle with effort-dependent tests such as spirometry.

Oscillometry techniques, such as Impulse Oscillometry System (IOS) and Forced Oscillation Technique (FOT), provide noninvasive lung mechanics measurements during quiet breathing, making them especially useful in pediatric, elderly, and severely symptomatic patients where traditional spirometry is limited. Industry and clinical communities are responding with new product developments and partnerships, such as the introduction of portable oscillometry devices (e.g., tremoflo C2) and strategic collaborations that integrate oscillometry into broader respiratory diagnostics portfolios in the US, reflecting increased clinical adoption and accessibility. Persistent disease prevalence and technological advancements are key factors supporting the growth of the US oscillometry market.

Diagnostic Support for the Growing Geriatric Population to Provide Market Opportunities in Future

With the global increase in life expectancy, there is a massive opportunity to serve the geriatric population, where the prevalence of respiratory conditions is highest. The CDC (2023) reported that COPD prevalence in the US peaks at 10.5% for individuals aged 75 and older. Similarly, the Australian Bureau of Statistics (2022) found that 7.0% of Australians over 65 live with COPD. Many elderly patients suffer from physical frailty or cognitive impairment, making traditional spirometry nearly impossible. Oscillometry, which requires only 30 seconds of tidal breathing, offers a non-invasive and easy-to-perform alternative. Recent product developments in 2024 include gravity-independent oscillometers that can be used while the patient is reclining or in a hospital bed. This technical flexibility ensures that the most vulnerable age group receives accurate diagnostic staging without physical strain. This opportunity is underscored by the WHO's 2024 focus on healthy aging, which advocates for more accessible diagnostic tools for chronic conditions in older adults.

World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), American Chemical Society Publications, The U.S. Centers for Medicare & Medicaid Services (CMS), US Department of Health & Human Services, Public Health Agency of Canada (PHAC), French National Institute of Health and Medical Research (INSERM), Italian National Institute of Health (ISS), The Korean Journal of Internal Medicine, the Saudi Press Agency (SPA), UAE Ministry of Health and Prevention (MOHAP) are among the primary and secondary sources referred to while preparing the Oscillometry Market report.